Subscribe
9 October 2014Asia-Pacific

‘Worrying trend’ of Aussie counterfeit pharmaceuticals

Criminal gangs in Australia are branching away from traditional forms of counterfeiting and are targeting pharmaceuticals, an Australian customs official has revealed.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
Australia criticised over ‘excessive’ protection for pharma patents
4 May 2016   Australia’s patent system is “poorly targeted” and protection for pharmaceutical inventions is “excessive”, according to a government advisory committee.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Asia-Pacific
Australia criticised over ‘excessive’ protection for pharma patents
4 May 2016   Australia’s patent system is “poorly targeted” and protection for pharmaceutical inventions is “excessive”, according to a government advisory committee.

More on this story

Asia-Pacific
Australia criticised over ‘excessive’ protection for pharma patents
4 May 2016   Australia’s patent system is “poorly targeted” and protection for pharmaceutical inventions is “excessive”, according to a government advisory committee.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory